AbbVie Inc.
ABBV
주식 순위
#25
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery,... AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
주가
$285.11
마지막 동기화: 2026-10-16
시가총액
$503.82B
변동 (1일)
0.78%
변동 (1년)
24.37%
국가
US
거래 AbbVie Inc. (ABBV)
카테고리
Healthcare
AbbVie Inc. (ABBV)의 배당 이력
AbbVie Inc. (주식 심볼: ABBV)은 총 39회의 배당금을 지급했습니다.
모든 배당금의 합계 (주식 분할 반영): $45.62
배당 수익률 (TTM): 0.0287
모든 배당금의 합계 (주식 분할 반영): $45.62
배당 수익률 (TTM): 0.0287
AbbVie Inc. (ABBV)의 2016부터 2026까지 배당 지급 내역
연간 배당 지급
| 연도 | 배당금 (주식 분할 조정됨) | 변화 |
|---|---|---|
| 2026 (TTM) | $1.49 | -73.97% |
| 2025 | $5.73 | -7.54% |
| 2024 | $6.20 | 4.73% |
| 2023 | $5.92 | 5.01% |
| 2022 | $5.64 | 8.42% |
| 2021 | $5.20 | 10.17% |
| 2020 | $4.72 | 24.23% |
| 2019 | $3.80 | 14.37% |
| 2018 | $3.32 | 35.02% |
| 2017 | $2.46 | 115.82% |
| 2016 | $1.14 | 0.00% |
모든 배당 지급 목록
| 연도 | 배당금 | 변화 |
|---|---|---|
| 2026 (TTM) | $1.49 | -73.97% |
| 2025 | $5.73 | -7.54% |
| 2024 | $6.20 | 4.73% |
| 2023 | $5.92 | 4.96% |
| 2022 | $5.64 | 8.46% |
| 2021 | $5.20 | 10.17% |
| 2020 | $4.72 | 24.23% |
| 2019 | $3.80 | 14.37% |
| 2018 | $3.32 | 35.02% |
| 2017 | $2.46 | 115.82% |
| 2016 | $1.14 | 0.00% |
유사 기업 또는 경쟁사의 배당 지급
| 회사 | 배당 지급 횟수 | 국가 |
|---|---|---|
| 215.00% |
US
|
|
| 225.00% |
US
|
|
| 33.00% |
CH
|
|
| 223.00% |
US
|
|
| 29.00% |
CH
|
